![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessEffect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group
-
Article
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group
Daratumumab (DARA) is a human IgG-K monoclonal antibody (MoAb) targeting CD38 that is approved alone or in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone for relapsed or refrac...
-
Article
Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma
A working group of six expert physicians convened to assess the spectrum of multiple myeloma relapse presentations, discussed the features that can define the disease as aggressive and not aggressive, and esta...
-
Article
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide–dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾65 years ...
-
Article
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus lenalidomide (CC+R). Salvage ASCT at first relapse may stil...
-
Article
Open AccessOlaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
-
Article
Open AccessA randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). Rel...
-
Article
An observational study assessing peripheral neuropathy related to multiple myeloma
We aimed at assessing the prevalence of peripheral neuropathy in newly diagnosed, treatment-naïve patients with multiple myeloma. We enrolled 153 patients with multiple myeloma at initial diagnosis. All patien...
-
Article
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma
This phase 2 trial evaluated three low-dose intensity subcutaneous bortezomib-based treatments in patients ⩾75 years with newly diagnosed multiple myeloma (MM). Patients received subcutaneous bortezomib plus o...
-
Article
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
-
Article
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia
-
Article
Open AccessReview of health-related quality of life data in multiple myeloma patients treated with novel agents
In multiple myeloma (MM), health-related quality of life (HRQoL) data is becoming increasingly important, owing to improved survival outcomes and the impact of treatment-related toxicity on HRQoL. Researchers ...
-
Article
Peripheral nociceptor sensitization mediates allodynia in patients with distal symmetric polyneuropathy
Patients with painful neuropathy frequently complain of pain in response to normally non-painful brushing, namely dynamic mechanical allodynia. Despite many animal studies suggesting that allodynia arises when...
-
Article
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
Lenalidomide has raised concerns regarding its potential impact on the ability to collect stem cells for autologous stem cell transplantation, especially after prolonged exposure. The use of cyclophosphamide p...
-
Article
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
This multicenter, open-label, non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refra...
-
Article
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
We present a pooled update of two large, multicenter MM-009 and MM-010 placebo-controlled randomized phase III trials that included 704 patients and assessed lenalidomide plus dexamethasone versus dexamethason...
-
Article
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias
The aim of the study was to evaluate the antileukemic effectiveness and toxicity of high-dose hydroxyurea (HHY) and to assess its acute toxicity. Between August 1997 and October 1998, 12 consecutive adult pati...
-
Article
Cell cycle regulation and induction of apoptosis by IL-6 variants on the multiple myeloma cell line XG-1
Interleukin-6 (IL-6) serum levels and the proliferative activity of bone marrow plasma cells have been described as important prognostic factors for survival duration in multiple myeloma (MM) patients. Since ...
-
Chapter and Conference Paper
Poor-Risk Acute Myelogenous Leukemia Patients Undergoing the Fludarabine – Cytosine Arabinoside – Filgrastim Regimen: Multidrug Resistance Expression, Granulocyte Colony-Stimulating Factor Priming Activity and Clinical Response
Eleven poor-risk acute myelogenous leukemia (AML) patients were treated with fludarabine + cytosine arabinoside + granulocyte colony-stimulating factor (FLAG). The median age was 38 (range 31–51 years) and fiv...
-
Chapter and Conference Paper
Preclinical Evaluation of Granulocyte-Macrophage Colony-Stimulating Factor/Interleukin 3 Fusion Protein (PIXY 321) in Acute Myeloid Leukemic Cells
Hemopoietic growth factors (GFs) can stimulate proliferation of leukemia cells, such effect furnished a rationale for acute myeloid leukemia (AML) treatment based on priming of quiescent blasts into cell cycle...